Therapeutic | Ramucirumab |
Target | KDR |
Heavy Chain | EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS |
Light Chain | DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK |
100% seqID Fv Structure | 3s34 [Fvs: HL], 3s36 [Fvs: HL], 3s37 [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 3s34 [Fvs: HL] |
100% seqID Structure | 3s37 [Fvs: HL] |
100% seqID Structure | 3s36 [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | Dyax Human Phage Display |
INN Year Proposed | 2008 |
INN Year Recommended | 2009 |
Companies Involved | Dyax, AstraZeneca, Dana-Farber Cancer Institute, Eli Lilly, Merck Sharp & Dohme, University of Texas M. D. Anderson Cancer Center, Washington University School of Medicine |
Conditions Approved | Colorectal cancer, Gastric cancer, Non-small cell lung cancer, Liver cancer |
Conditions Active | Oesophageal cancer, Urogenital cancer, Biliary cancer, Carcinoid tumour, Solid tumours, Pancreatic cancer |
Conditions Discontinued | Breast cancer, Malignant melanoma, Ovarian cancer, Prostate cancer, Renal cell carcinoma |
Notes |